Dataset Information

Quantitative SWATH-Based Proteomic Profiling of Urine for the Identification of Endometrial Cancer Biomarkers in Symptomatic Women

ABSTRACT: In this study, we carried out quantitative SWATH-MS-based proteomic profiling of urine acquired from a cohort of symptomatic women with and without endometrial cancer.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Urine

DISEASE(S): Endometrial Carcinoma

SUBMITTER: Kelechi Njoku

LAB HEAD: Emma Crosbie

PROVIDER: PXD038860 | Pride | 2023-05-10

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 441

Publications

Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.

Njoku Kelechi K Pierce Andrew A Geary Bethany B Campbell Amy E AE Kelsall Janet J Reed Rachel R Armit Alexander A Da Sylva Rachel R Zhang Liqun L Agnew Heather H Baricevic-Jones Ivona I Chiasserini Davide D Whetton Anthony D AD Crosbie Emma J EJ

British journal of cancer 20230217 9

<h4>Background</h4>A non-invasive endometrial cancer detection tool that can accurately triage symptomatic women for definitive testing would improve patient care. Urine is an attractive biofluid for cancer detection due to its simplicity and ease of collection. The aim of this study was to identify urine-based proteomic signatures that can discriminate endometrial cancer patients from symptomatic controls.<h4>Methods</h4>This was a prospective case-control study of symptomatic post-menopausal w ...[more]

PMID: 36807337

Similar Datasets

Project description:TARGET (Tumour characterisation to Guide Experimental Targeted therapy) seeks to optimise the pathway for molecular characterisation of all patients entering early phase cancer trials to inform clinical decision-making on optimal therapy. Performance status (PS) was developed to assess a patient’s ability to perform a variety of activities to further inform clinical decision making on optimal therapy including appropriate inclusion in clinical trials. However, the quality of present algorithms to assess performance status are limited and based on a semi-quantitative clinician assessment. In particular, a common eligibility criterion for entry into early phase cancer clinical trials is a life expectancy of >3 or 6 months. Here we investigate proteomics as a means of more objective and quantitative assessment of both performance status and thus likely prognosis prior to clinical trial enrolment. Improved patient stratification at enrolment would reduce the number of patients unnecessarily exposed to potentially toxic drugs and decrease withdrawal from trials. Plasma samples from patients enrolled into the TARGET trial were analysed using the mass spectrometry (MS) technique: Sequential window acquisition of all theoretical fragment ion spectra (SWATH) MS. SWATH-MS was used on a discovery cohort of 73 patients to identify proteins that could differentiate patients into either a good or poor prognosis. A three-protein panel showed a stronger prediction of overall survival (p = 0.000086) compared to PS (p = 0.001). This panel was then tested against a validation cohort of 77 patients. The panel was determined as being a significant (p = 0.000451) predictor of overall survival whereas PS was not significant. The panel had a receiver operating characteristic curve area under the curve (AUC) of 0.73 in the validation set; the AUC of PS was 0.54. This signature can now be developed further in larger patient populations to assess its utility in a clinical setting.

			Action	DRS
	DKNUS01_100_1.wiff	Wiff
	DKNUS01_100_1.wiff.scan	Wiff
	DKNUS01_100_2.wiff	Wiff
	DKNUS01_100_2.wiff.scan	Wiff
	DKNUS01_101_1.wiff	Wiff